The Future of Combination Therapies for Cancer Treatment
10:45 AM - 12:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 253ABC
Immune checkpoint inhibitors have changed the way we treat cancer patients. However, only a fraction of cancer patients benefit from these treatments and further testing of combination therapies with checkpoint inhibitors is needed to broaden their utility and further improve outcomes. In this session, we will focus on the partnering strategies of leading biopharmacos in seeking collaborations for potential checkpoint inhibitor combinations. A particular focus will be on how radiation therapy in combination with checkpoint inhibitors may be beneficial in different clinical settings.
Expert Advisor, Oncology, Lumanity EVP, Head of Oncology Practice, BioConsulting Head of Oncology Center of Excellence
Vice President, General Manager of Research and Development and Chief Medical Officer
Senior Vice President, Business Development, Oncology, Hematology & Cell Therapy
Bristol Myers Squibb